This F1061S point substitution in the SEA domain of Agrin provides a viable model for congenital myasthenic syndrome type 8 (CMS8), with homozygotes showing degradation of neuromuscular junctions at varying rates in specific muscles, a phenotype which progresses to premature death.
The Jackson Laboratory cannot guarantee that cryorecovery of strains from the discontinued NIH-funded Neuroscience Mutagenesis Facility (NMF) will be successful or that the anticipated phenotype or genotype will be obtained. The cryorecovery fee for this effort will not be refunded or prorated if the recovery is unsuccessful or is in any way unsatisfactory. Genotyping will be the responsibility of the Purchaser.
Read More +Genetic Background | Generation |
---|---|
000664 C57BL/6J |
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Chemically induced (ENU) | Agrn | agrin |
Null alleles of agrin cause embryonic lethality with failed formation of neuromuscular junctions, but this F1061S point substitution in the SEA domain in the SN form of Agrin provides a viable model for congenital myasthenic syndrome type 8 (CMS8). Although no change was detected in transcript quantity or size and the alternative splicing at the Z splice site of exons 32 and 33 appears normal, this mutation is a partial loss of function hypomorph with decreased glycosylation of the mutant protein. Cell transfection studies show that this point mutation can decrease proteolysis of this protein by neurotrypsin and result in decreased externalization and secretion.
Agrnnmf380 homozygotes are generally smaller than littermate controls by 15 days of age, there is muscle stiffness and atrophy, with their hind limbs appearing to be too weak to carry the weight, remaining low during movement, and they generally die between a few weeks to a few months of age. Initial pathology assessment on three mutants (27 - 34 days of age) revealed neurogenic myopathy with small and regenerating muscle fibers. Toes, especially those of hind paws may not fully extend, and hind limbs may move together rather than alternate. Brief spasms of hind or front limbs can also be observed. When lifting the mice by their tail, hind limbs remain clasped to the body. They develop an intense body tremor during movement and at rest due to postnatal degradation of neuromuscular junctions that proceeds at different rates in different muscles. The onset of the outward phenotype is approximately 2 weeks of age, although some muscles show perinatal neuromuscular degeneration. Defects of the neuromuscular junctions include smaller, underdeveloped postsynaptic sites, diminished alpha-bungarotoxin staining indicating decreased acetylcholine esterase receptors, and motor nerve terminals that sprout beyond the endplates. Transmission electron microscopy of the neuromuscular junctions from the plantaris muscle at 20 days of age showed abnormalities including extensive subsynaptic reticulum not continuous with the plasma membrane and decreased acetylcholine esterase and beta-dystroglycan from the neuromuscular junction. Genetic background impacts the phenotype of Agrnnmf380, with the severity in homozygotes being similar when backcrossed to FVB/NJ, DBA/2J, or BALB/cJ, but much less severe when backcrossed to N3 on CAST/EiJ.
The degeneration of neuromuscular junctions in these mutants varies between different muscles. The diaphragm shows overgrowth of presynaptic endings and indistinct alpha-bungarotoxin staining by 1 day of age and almost no intact neuromuscular junctions by P14. The tibialis anterior appears normal in newborns, but by P14 disaggregating neuromuscular junctions are found. The neuromuscular junctions of the soleus appear normal at P4 but not by P14. The triangularis sterni show normal innervation at P9, but decreased alpha-bungarotoxin staining and abnormal presynaptic morphology by P13, and by P18 the neuromuscular junctions were found to be degraded both pre- and post-synaptically. However, the extraocular muscles do not show neuromuscular degeneration at P30. Assessment of the tibialis anterior and gastrocnemius muscles found that neuromuscular disaggregation and denervation occurs in the medial before the intermediate region. It is worthy of note that retraction or degeneration of the axons of peripheral nerves was not found. (Bogdanik and Burgess, 2011.)
This phenotypic deviant was generated by ethylnitrosourea (ENU) mutagenesis in C57BL/6J males (Stock No. 000664), in the Neuroscience Mutagenesis facility at The Jackson Laboratory. Mutagenized males were crossed to C57BL/6J females; G3 descendants of the mutagenized males were selected for neurological impairment.
Allele Name | neuroscience mutagenesis facility, 380 |
---|---|
Allele Type | Chemically induced (ENU) |
Allele Synonym(s) | NMF380 |
Gene Symbol and Name | Agrn, agrin |
Gene Synonym(s) | |
Strain of Origin | C57BL/6J |
Chromosome | 4 |
Molecular Note | This phenotypic mutation was identified in an ENU mutagenesis screen. The molecular mutation is an A to G conversion, resulting in the change of phenylalanine 1061 to serine (F1061S, numbered according to the SN form of the protein) in the SEA domain of the encoded protein. |
These mutants are fragile and need special care to live beyond 6 weeks of age. Colony maintenance should use heterozygotes or ovarian transplantation and removal of unaffected littermates may improve the survival of the remaining mutant pups given increased maternal attention.
When using the C57BL/6J-Agrnnmf380/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #005469 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Unknown for nmf380 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.